Reports Q4 revenue $249.3M, consensus $250.63M. Chris Simon, Haemonetics’ CEO, said: “We are pleased with our strong finish to Fiscal 2019. We launched NexSys, the platform we believe is best positioned to support plasma industry growth. We also continued to reduce complexity and costs to meaningfully expand our profit margins, while freeing up resources to invest in growth. Our positive results are evidence that our strategy is sound and creating momentum for additional revenue and profitability growth in Fiscal 2020 as we drive our corporate-wide transformation.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.